9.04.20
8 min. Read

New Teladongo merger details. Pear’s acquisitive study strategy.

Issue 068

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Amwell's IPO filing and the possible longterm repercussions of Amazon's move into voice biomarkers via its first wearable device, Halo. Here's what's happening this week:

  • Teladoc-Livongo revealed more information about their multi-billion dollar merger in a lengthy government

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
12.15.23
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
12.01.23
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
10.20.23
6 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
10.06.23
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
9.29.23
6 min. Read
CMS: PDTs have potential. Trials: Big, Koko, GAIA
9.22.23
6 min. Read
Limbix acquisition price tag. Akili fully pivots to OTC.
9.15.23
6 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last